Pharma BD Deal Intelligence
AstraZeneca paid $105M upfront ($25M cash plus $80M equity at $5.00/share) for a TALEN-based collaboration spanning up to 10 Cellectis programs, later doubling down with an additional $140M equity investment to reach roughly 44% of share capital.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca is pushing further into cell and gene therapy with a $2.2 billion potential deal with Cellectis covering up to 10 candidates. The pharma giant will…
AstraZeneca and Cellectis announced a research collaboration to design novel cell and gene therapy candidates leveraging Cellectis' TALEN gene-editing…
Cellectis FY2024 results: three programs are in initial development under the AZ JRCA — one allogeneic CAR-T for hematological malignancies, one allogeneic…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
AstraZeneca entered a research collaboration and equity investment with Cellectis (Nasdaq/Euronext: CLLS) on November 28, 2023 to design up to 10 cell and gene therapy candidates across oncology, immunology and rare disease using Cellectis' TALEN gene-editing platform and manufacturing capabilities. AstraZeneca paid $105M initially ($25M upfront cash plus an $80M equity investment at $5.00/share, ~22% stake), with each of the up to 10 candidate products eligible for an IND option fee plus development, regulatory and sales milestones ranging from $70M up to $220M per product, plus tiered royalties. AstraZeneca subsequently completed an additional $140M equity investment at $5.00/share on May 6, 2024 (after French Ministry of Economy clearance and Cellectis shareholder approval), lifting its stake to approximately 44% of share capital / 30% of voting rights and adding two AstraZeneca directors to the Cellectis board. By December 31, 2024 three programs were in initial development under the joint research collaboration agreement (two allogeneic CAR-T candidates for hematological malignancies and solid tumors, and one in vivo gene therapy for a genetic disorder), with $47M paid to Cellectis to date ($25M upfront plus $22M in development milestones). The collaboration remained active as of January 2026. AstraZeneca's equity backing extends Cellectis' cash runway into mid-2027.
187K US cases/yr · $82.0B Global cell & gene therapy market forecast (2032) · 2200 Total Cellectis-AZ potential deal value across up to 10 programs (USD MM)
Gene-edited cell and in vivo gene therapies address severe and genetically defined diseases across oncology, hematology, immunology and rare disease. AstraZeneca's target patient populations through the Cellectis collaboration span CAR-T-eligible hematologic malignancies, solid tumors amenable to engineered cell approaches, autoimmune/immunology indications (e.g., systemic lupus erythematosus, myasthenia gravis, refractory autoimmune syndromes) and rare inherited hematologic diseases such as sickle cell disease and beta-thalassemia. US hematologic malignancy incidence is approximately 187,000 cases annually (SEER 2023), with roughly 20,000 CAR-T-eligible patients per year. Autoimmune gene-editing opportunities expand the addressable population substantially (SLE alone affects ~322,000 US adults, NHIS/CDC). TALEN-based editing differentiates from CRISPR on precision (no gRNA-mediated off-target risk) and IP freedom, positioning non-viral in vivo delivery as the next frontier after approved ex vivo CRISPR (Casgevy, 2023). The broader cell and gene therapy market is forecast to reach $82B by 2032 (EvaluatePharma) as next-wave in vivo editing platforms mature and allogeneic off-the-shelf formats address cost-of-goods barriers.
Gene editing platform competition has consolidated around four modalities, each with distinct IP and delivery profiles. Ex vivo CRISPR/Cas9: Casgevy (exa-cel, Vertex/CRISPR Therapeutics, approved December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia) validated the category; Lyfgenia (lovo-cel, bluebird bio) is a lentiviral competitor in SCD. Ex vivo base editing: Beam Therapeutics' BEAM-101 (autologous SCD) and Verve's VERVE-101/102 in cardiovascular disease. Ex vivo TALEN: Cellectis' own UCART22 and UCART20x22 (Phase 1 in B-ALL and NHL) are the first wholly-owned allogeneic CAR-T programs in the class. In vivo LNP-delivered editing: Intellia's NTLA-2001 (nex-z, Phase 3 in ATTR amyloidosis) and NTLA-2002 (hereditary angioedema), plus the Verve cardiovascular editors. Allogeneic CAR-T competitors: Allogene's ALLO-501A, Caribou Biosciences' CB-010 and Poseida's P-BCMA-ALLO1. Approved CAR-T benchmarks: Kymriah (Novartis), Yescarta and Tecartus (Gilead/Kite), Breyanzi (Bristol Myers Squibb), Abecma and Carvykti (BMS/J&J and Legend). AstraZeneca entered the TALEN arena to secure non-CRISPR editing IP, compete with the Lilly/Verve base-editing axis, and arm its Alexion rare-disease and immunology franchise with non-viral, potentially redosable gene therapy capability against Regeneron, Vertex, Roche/Genentech and Novartis.
The November 2023 research collaboration and initial $80M equity investment ($5.00/share, ~22% stake) plus $25M upfront cash completed in Q1 2024.
AstraZeneca completed a further $140M equity investment in Cellectis at $5.00/share on May 6, 2024 following French Ministry of Economy clearance, raising its stake from ~22% to ~44% of share capital / 30% of voting rights and adding two directors to the Cellectis board.
By year-end 2024, three programs were in initial development (two allogeneic CAR-T and one in vivo gene therapy). Cellectis had received $47M under the AZ JRCA ($25M upfront + $22M development milestones). Cash runway funded into mid-2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Cellectis SA (this deal) | 2023 | $605M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Immunology deals